his is the first site to open for this interesting clinical trial using both Zytiga (abiraterone) and Xofigo (radium 223).
All men will receive Zytiga + prednisone. Some men will receive Xofigo, some will receive placebo instead of Xofigo.
Clinic visits are every 4-weeks for six months during treatment.
Basic Eligibility Criteria for this trial:
Castrate resistant (Testosterone less than 50 w/ rising PSA)
2 or more bone metastases
NO lung, liver, or other soft tissue metastases
NO previous chemo
NO previous Zytiga (abiraterone)
NO previous Xofigo or Samarium
Little or no cancer pain
NO atrial fibrillation, Crohn's disease, or ulcerative colitis
Arizona Molecular Imaging
Elisa Blackwell 602.331.1771
Other locations to follow - View this link at ClinicalTrials.gov **